SOHM Inc (PK) (SHMN) Share Price

LOL

all we need are tattoos !

We are being tested, Grasshopper!

this stock would test the patience of a Shaolin monk.....

To your points SLCJD: Advancements in Cell and Gene Therapies

"The momentum behind cell and gene therapies continues to gain steam, particularly with exciting developments in treating conditions like type 1 diabetes. Recently, for example, Sana Biotechnology announced promising data in one patient in a first-in-human allogeneic cell therapy for type 1 diabetes — without immunosuppression.

And Bayer, together with our subsidiary BlueRock Therapeutics, announced plans to initiate a Phase III trial for its allogeneic investigational cell therapy for Parkinson’s disease, based on compelling data from the Phase I trial.

These examples, among others, are creating high hopes for cell and gene therapies, as they begin to demonstrate positive human data."

5 Insights From The 2025 JP Morgan Healthcare Conference
https://www.forbes.com/sites/juergeneckhardt/2025/01/16/5-insights-from-the-2025-jp-morgan-healthcare-conference/

And: An Increase In Dealmaking Activity
"One of the most notable trends is the resurgence of dealmaking in the pharmaceutical sector. In 2024, we saw 106 biotech venture deals exceeding $100 million, signaling a bounce back from previous downturns. The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent cliff for many drug developers. With an estimated $400 billion in revenue losses expected from patent expirations between now and 2033, the urgency to refill pipelines is great. This year, I predict we will witness an uptick in both early and late-stage asset acquisitions, like Eli Lilly’s acquisition of Scorpion Therapeutics, as companies look to secure innovative therapies that can make a significant impact on patient care. That said, the larger financing sizes will also be tied to ensuring companies pass critical testing milestones."

And taking a look backward:

Coastar Therapeutics to Present in JP Morgan Conference Events
SAN DIEGO, January 5, 2023 – Coastar Therapeutics Inc., a biotechnology company developing novel delivery technologies to supercharge cell and gene therapies, announced that it will be presenting at events of the 42nd JP Morgan Healthcare Conference, January 8-11 in San Francisco.

Coastar’s innovative cell membrane coating technology platform enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease targets. The technology can lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

“We are truly excited to be presenting during the JP Morgan week of events.” said Eddie Y. Chung, CEO of Coastar Therapeutics, “In the past 12 months, the Coastar team has made tremendous progress in developing our erythrocyte membrane based gene delivery platform. From local injection to systemic delivery, from viral to non-viral payloads, from oncology to gene therapy, we are generating important data and achieved great levels of efficacy and precision in delivery. I look forward to meeting and sharing our progress with colleagues and partners at JPM.”

“JPM is the week of premier events where the entire industry convenes and deals are made,” said Dr. Chongyang Luo, Chief Operating Officer of Coastar, “We are excited to meet up with our current and prospective partners. The industry realizes that effective and targeted gene delivery is a bottleneck to better and cost-effective therapies. Coastar is on track to break the bottleneck and supercharge cell and gene therapy.”

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnSTM and eLNPTM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites. The company is working with a number of global partners to help deliver their drugs.

SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Ce?id=435326

https://x.com/sohminc/status/1874344120971587899

https://x.com/sohminc/status/1856048539803230341

"We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.

The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025."

____
That was Nov 11, 2024. 10 weeks ago. We are overdue, imo.

You're absolutely correct, but I'm pretty sure that a former employee/consultant who left on less than great terms won't have the kind of comments that will lead to more investor confidence.

Proof (one way or the other) will be in the pudding on 3/31 and/or 5/15. Until then, anything anyone says are just more words with very little substance.

Any input is appreciated. Investors simply have no confidence at this point. The constant downward spiral reflects that. Is the future bright? Yes. But they are all words and very little substance. Any informative comments need to be expressed.

thank you, and best of luck going forward D.R.

I hope you worked things out...

My appologies to the group for posting inappropriate personal information on this site. I have full faith in SOHM as a company and its Board of Directors. I will exit the chatroom as a member as i dont want to influence in any way the group's comments or feedback to company updates. DrSmith9

2.5 millon dumped on the bid, it's never ending.

seems someone knows there's no viable news this week, they are usually right..

It would seem with the new administration, any new tech by a US company would be a gold mine. Let's see if ABBIE lives up to the hype

The easiest way to regain some credibility is to find another CEO, this one has worn out his welcome as far as I'm concerned.

A share buyback would be great except they don't have the money.

Now if they start selling ABBIE Kits/ License deals the money should start coming in....

Agreed. A buyback is needed. I have been pushing for this. They need to regain credibility. Show to investors they believe in the work they have been putting in for over a year now. You can’t buy a home in California for the market cap of this company. They should be buying at these absurdly depressed levels.

keep low bids in, the weekly walk down has commenced, ground hog week....

I tend to agree with that JD, but no one knows where ABBIE is headed. The OS for instance could be lowered with some serious share buyback, yeah, someone had to say it, might as well be me. Initial sales, if good, could pay for that easily.

SHMN shares are not being introduced to the right people by the co. Are they trying ?

With ABBIE having so much potential it boggles my mind that anyone that follows genome editing technology would not want to invest.

Especially at triple 7.....

this stock will go through the roof. We are talking into the dollar range and higher

I applaud your enthusiasm, but it's probably wise to temper your expectations.

SHMN currently has 1.998 billion shares outstanding; there's no way (barring a short squeeze) that this company justifies a $2BB market cap.

I expect to see a penny plus if the annual/Q1 reports show revenue, and hope for a nickel. I dream of a dime, but even that's pushing the limits of feasibility based solely on market cap implications (currently looking at the chart of a $300MM/yr Nasdaq company with a market cap of $350MM).

no problem, this thing ever goes back to copper and I'm buying a case of each flavor.....

I need a Gummie...

Don't forget to bring enough to share with the rest of us!

yep, James Bond would surely look better....

I need a Gummie...

Heck, getting rid of one of those decimal trailing zeroes would cheer me up!

I think it's going to take a combination of news and earnings to make this move. This company has a lengthy history of making splashy announcements with little to no follow-through. While a PR used to move the needle, they're all but ignored these days.

I think/hope that this era has passed, but until some of their more recent announcements (including the EOY video shared on this board) result in tangible revenue as reflected in a quarterly/annual report, potential investors have no reason to believe what they're saying.

March 31 (2024 annual) and/or May 15 (2025 Q1) will be instructive as to whether they really have turned the corner; I don't anticipate any actual movement in PPS until those reports come out.

right now above sea level would be nice !

lol....

To infinity and beyond!

Unfortunately, until there is some BIG news posted across multiple platforms and channels this stock will stay dormant hopefully with everything in play they can release a solid PR to potential whale investors ready to jump on board and send this stock into penny land otherwise we will be stuck in the sub basement. 

Nice graph on FDA Approved Cell and Gene therapies:

https://www.linkedin.com/posts/joanna-sadowska-phd_approval-fda-genetherapy-activity-7284554822131798017-e1to?utm_source=share&utm_medium=member_android


----

"We will be releasing additional information regarding our position in Europe and Korea in the near future."

3:00 minute mark: https://x.com/sohminc/status/1874344120971587899

Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization

https://www.globaldata.com/companies/top-companies-by-sector/healthcare/europe-companies-by-market-cap/#:~:text=Top%2010%20Pharmaceutical%20Companies%20in%20Europe%20in%202022%20by%20Market%20Capitalization,-Share&text=Showing%2010%20out%20of%2023,of%20Mar%2031%2C%202023).

Top 10 Pharma Companies in South Korea by Market Cap

https://www.globaldata.com/companies/top-companies-by-sector/healthcare/south-korea-companies-by-market-cap/#:~:text=Celltrion%20Inc%20is%20the%20leading,It%20employs%201%2C067%20people.

Good morning, checking with this stock again to see if I can recover any money. Tried erasing my previous comments but the system does not allow to delete posts.

Market closed today, but keep low bids in place until the co makes a worthwhile announcement.

I have too. The video says a mouthful. I was going to ask someone to create a transcript from it, and would like a PR of the contents even better.

Aguillar said things not yet fully elaborated. Like the ongoing collaborations with Stanford, Coastar, and Universal Sequencing.

11 patents applications/approvals...up from 4 the beginning of 2023.

He was also noticeably animated when he mentioned they have one of "the best patent IP firms, Knobbe Martens." (Something only mentioned before in filings.)

(More could also be mentioned about his confirmation of continuing Brainwise orders, and the development of IProlec, though of lesser concern to me than ABBIE)

Also, Manufactuting license in California for Carlsbad, and Wholesale license in New Jersey.
(Significance yet unknown as related to Levitiracetam)

So much to mention...thus a transcript of the video would be nice.

Passing mention...San Diego is still "under consideration" pending manufacturing ok from the city of San Diego.

_______________

As you can see, I've been thinking about the video too, all the above is off the top of my head, as I've watched the video several times like you.

Thanks for your post on the mentioned 3 possibilities. We are so overdue for a game changing PR, imo. Respects SLC-JD.

I've been thinking a lot about this video over the last few days...

There are 3 main reasons to pursue a robust patent portfolio:

1) 'offensive' - The company has created or acquired a novel invention, wishes to monetize it through direct sales or licensing, and wants to make sure that its competitors cannot utilize it (this use case also applies to patent trolls)

2) 'defensive' - The company has created or acquired a novel invention, wishes to monetize it through direct sales or licensing, and wants to make sure that its competitors cannot deprive them of the ability to do so.

3) 'blue sky' - The company has created or acquired a novel invention, and while it may not be positioned to monetize it fully, acknowledges that it is a thing of value which may be desirable to others and moreover, may make the company a more desirable acquisition target.

I imagine the coming months will help to clarify which of these positions is being undertaken by SHMN, but my gut keeps telling me that we're probably looking at number 3.

This company is so undervalued all is going to take is for the pieces of the puzzle to finally come together after years and this stock will go through the roof. We are talking into the dollar range and higher I have held onto the stock for well over five years I bought in onceand I've been sitting and waiting in the end is coming soon. 

Hope everyone had a great holiday season. 2025 is when SHMN said ABBIE was going to take off. Let's see what they do.

Aguilar has now confirmed in this new video, that Sohm is collaborating with "Universal Sequencing." (This is the Company that Kawamura works part time for.)

See my linked back post.

SOHM 2025 Momentum and 2024 Recap!

https://twitter.com/sohminc/status/1874344120971587899?t=rWIfnpO9V44NiQnWIW266w&s=19

Walmart Marketplace: "We are glad to share that the company has received approval from Walmart Marketplace to sell our products on its platform. In the next few days as we progress, we will start putting our products on it. This development is another milestone for the company and we are very excited with the development."

https://x.com/sohminc/status/1871252518602485892

I could have sworn I already said that.

Good luck and Happy Festivus to you.

If so, they'd have to wait 30 days to avoid the wash sale rule.

https://www.linkedin.com/posts/joanna-sadowska-phd_pharma-biotech-cancer-activity-7276219880725446657-Rj2l?utm_source=share&utm_medium=member_android

I'm hoping that it is mostly tax-loss selling. The logic being that you can get them back at a tad more 30 days hence. I guess we'll see.

Big bid at .0007s, is that the bottom? Some news about actual ABBIE kit sales would go a long way here.

Well, at least we have something to hope for in this one which is rare in penny land!

After 6+ years it gets easier LOL

if Tom Petty said it HAS to be true....lol...

it was very informative, love this..

how it ABBIE we be an evolving product.

The waiting....is the hardest part!

Just something he sent me that he posted on LinkedIn yesterday.

Gives a little insight to what his plan is with Abbie going forward. and how it ABBIE we be an evolving product.not a stagnant on time sale item.

I didn't hear him mention any sales so far, did I miss something ?

with the annual due 3/31 and the quarterly due 5/15 that's a 6 week window that actual shareholders would have to wait.

waiting is what we do best......